Fuzi alkaloids play a therapeutic role by converting the metabolic pathway from glycolysis to oxidative phosphorylation in NSCLC by inhibiting PI3K/Akt/mTOR pathway phosphorylation, as well as by promoting the restoration of TCA cycle activity. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.